It adds Rezurock (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD)
Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old
Advances deployment of mRNA technology across vaccines and therapeutics development
Revenue increased 11.4 per cent to Rs. 8,545 crore
Mistry is a seasoned finance professional having an extensive work experience spanning more than 25 years
Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
Phase 3 study results will form the basis for future discussions with global regulatory authorities
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
Subscribe To Our Newsletter & Stay Updated
